Essa Pharma Stock Performance
| EPIX Stock | USD 1.68 0.02 1.18% |
The firm shows a Beta (market volatility) of -0.13, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning ESSA Pharma are expected to decrease at a much lower rate. During the bear market, ESSA Pharma is likely to outperform the market. At this point, ESSA Pharma has a negative expected return of -0.0473%. Please make sure to confirm ESSA Pharma's treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if ESSA Pharma performance from the past will be repeated at future time.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days ESSA Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong forward indicators, ESSA Pharma is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
Last Split Factor 1:20 | Dividend Date 2018-04-25 | Last Split Date 2018-04-25 |
1 | Eikonizo Therapeutics Announces Investment by Novo Nordisk Advancing Lead Candidate EKZ-102 Toward Clinical Development | 12/10/2024 |
2 | The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in ESSA Pharma Inc. Lawsuit EPIX | 01/29/2025 |
3 | ESSA Pharma Inc. Class Action The Gross Law Firm Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March ... | 02/12/2025 |
4 | Levi Korsinsky Notifies ESSA Pharma Inc. Investors of a Class Action Lawsuit and Upcoming Deadline EPIX | 02/13/2025 |
5 | ROSEN, GLOBAL INVESTOR COUNSEL, Encourages ESSA Pharma Inc. ... | 02/14/2025 |
6 | Investors who lost money on ESSA Pharma Inc. should contact Levi Korsinsky about pending Class Action - EPIX | 02/18/2025 |
7 | Levi Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in ESSA Pharma Inc. Lawsuit EPIX | 02/21/2025 |
8 | Bragar Eagel Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed ... | 02/25/2025 |
9 | The Gross Law Firm Notifies ESSA Pharma Inc. Investors of a Class Action Lawsuit and Upcoming Deadline EPIX | 02/26/2025 |
10 | EPIX INVESTOR ALERT Bronstein, Gewirtz Grossman LLC Announces that ESSA Pharma Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Laws... | 02/27/2025 |
| Begin Period Cash Flow | 33.7 M |
ESSA |
ESSA Pharma Relative Risk vs. Return Landscape
If you would invest 175.00 in ESSA Pharma on December 1, 2024 and sell it today you would lose (7.00) from holding ESSA Pharma or give up 4.0% of portfolio value over 90 days. ESSA Pharma is currently does not generate positive expected returns and assumes 2.0666% risk (volatility on return distribution) over the 90 days horizon. In different words, 18% of stocks are less volatile than ESSA, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ESSA Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ESSA Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ESSA Pharma, and traders can use it to determine the average amount a ESSA Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0229
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EPIX |
Estimated Market Risk
| 2.07 actual daily | 18 82% of assets are more volatile |
Expected Return
| -0.05 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average ESSA Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ESSA Pharma by adding ESSA Pharma to a well-diversified portfolio.
ESSA Pharma Fundamentals Growth
ESSA Stock prices reflect investors' perceptions of the future prospects and financial health of ESSA Pharma, and ESSA Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ESSA Stock performance.
| Return On Equity | -0.24 | ||||
| Return On Asset | -0.17 | ||||
| Current Valuation | (46.02 M) | ||||
| Shares Outstanding | 44.39 M | ||||
| Price To Earning | (1.12) X | ||||
| Price To Book | 0.62 X | ||||
| EBITDA | (23.5 M) | ||||
| Net Income | (28.54 M) | ||||
| Cash And Equivalents | 174.6 M | ||||
| Cash Per Share | 3.96 X | ||||
| Total Debt | 329.26 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 43.43 X | ||||
| Book Value Per Share | 2.68 X | ||||
| Cash Flow From Operations | (22.72 M) | ||||
| Earnings Per Share | (0.69) X | ||||
| Market Capitalization | 74.57 M | ||||
| Total Asset | 128.11 M | ||||
| Retained Earnings | (208 M) | ||||
| Working Capital | 124.26 M | ||||
| Current Asset | 10.02 M | ||||
| Current Liabilities | 3.63 M | ||||
About ESSA Pharma Performance
Evaluating ESSA Pharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if ESSA Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ESSA Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 298.3 K | 313.3 K | |
| Return On Tangible Assets | (1.76) | (1.68) | |
| Return On Capital Employed | (1.34) | (1.40) | |
| Return On Assets | (1.21) | (1.15) | |
| Return On Equity | (1.71) | (1.62) |
Things to note about ESSA Pharma performance evaluation
Checking the ongoing alerts about ESSA Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ESSA Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ESSA Pharma generated a negative expected return over the last 90 days | |
| ESSA Pharma may become a speculative penny stock | |
| Net Loss for the year was (28.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ESSA Pharma currently holds about 174.6 M in cash with (22.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| ESSA Pharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 71.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: EPIX INVESTOR ALERT Bronstein, Gewirtz Grossman LLC Announces that ESSA Pharma Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit |
- Analyzing ESSA Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ESSA Pharma's stock is overvalued or undervalued compared to its peers.
- Examining ESSA Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ESSA Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ESSA Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ESSA Pharma's stock. These opinions can provide insight into ESSA Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for ESSA Stock Analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.